The head of Swiss pharmaceutical giant Novartis, Vasant Narasimhan, sees major growth opportunities in China despite its shrinking population. “If you look at the unmet need in China for the treatment of many chronic diseases, it is significant,” Narasimhan said.
Continue reading now
… and get free access to this Professional Briefing for a month.
Are you already a guest at the China.Table? Log in now